BiotechTube

Cabergoline

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Restless Legs Syndrome

Conditions

Restless Legs Syndrome

Trial Timeline

Nov 1, 2002 → May 1, 2003

NCT ID
NCT00627003

About Cabergoline

Cabergoline is a phase 3 stage product being developed by Pfizer for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00627003. Target conditions include Restless Legs Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00627003Phase 3Completed

Competing Products

20 competing products in Restless Legs Syndrome

See all competitors
ProductCompanyStageHype Score
Gabapentin enacarbilAstellas PharmaApproved
85
ASP8825Astellas PharmaPhase 3
77
RegniteAstellas PharmaPre-clinical
23
ASP8825 + PlaceboAstellas PharmaPhase 2
52
Placebo + Gabapentin enacarbilAstellas PharmaApproved
85
Apomorphine Sublingual Film + PlaceboSumitomo PharmaApproved
85
SuvorexantMerckApproved
85
Placebo + pregabalin + pregabalinPfizerPhase 3
76
placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + PregabalinPfizerPhase 2
51
pregabalin + placebo + pramipexolePfizerPhase 3
76
placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexolPfizerPhase 3
76
cabergoline + levodopaPfizerPhase 3
76
RotigotineUCBPhase 3
74
Neupro®UCBPre-clinical
20
Rotigotine Nasal SprayUCBPhase 2
49
RotigotineUCBPhase 3
74
Levetiracetam (Keppra)UCBPhase 2
49
Rotigotine + PlaceboUCBApproved
82
RotigotineUCBPhase 2
49
RotigotineUCBPhase 3
74

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84